4993-93-5

Usage

Uses

Used in Pharmaceutical Industry:
Ethyl 4-nitro-1H-indole-2-carboxylate is used as a building block for the synthesis of various pharmaceuticals. Its unique chemical structure allows it to be incorporated into the development of new drugs, potentially leading to the discovery of novel therapeutic agents.
Used in Agrochemical Industry:
In the agrochemical industry, ethyl 4-nitro-1H-indole-2-carboxylate is utilized as a precursor in the synthesis of various agrochemicals. Its chemical properties make it suitable for the development of new pesticides, herbicides, and other agricultural chemicals, contributing to improved crop protection and yield.

InChI:InChI=1/C11H10N2O4/c1-2-17-11(14)9-6-7-8(12-9)4-3-5-10(7)13(15)16/h3-6,12H,2H2,1H3

Upstream product

• 851786-38-4 ethyl 3-(2,6-dinitrophenyl)pyruvate 
• 1388183-69-4 ethyl 1-hydroxy-4-nitroindole-2-carboxylate 
• 606-20-2 2,6-dinitrotoluene 
• 51516-96-2 3-nitrophenylhydrazine hydrochloride 
• 99-09-2 3-nitro-aniline 
• 1056933-72-2 (E)-ethyl 2-(2-(3-nitrophenyl)hydrazono)propanoate 
• 134747-25-4 ethyl 2-[2-(3-nitrophenyl)hydrazinylidene]propanoate 

Downstream Products

• 33858-35-4 ethyl 4-amino-1H-indole-2-carboxylate 
• 220677-29-2 Ethyl N-(3,4-dichlorobenzyl)-4-nitroindole-2-carboxylate 
• 112089-66-4 5-(benzylamino)-1H-indole-2-carboxylic acid 
• 112089-67-5 ethyl 5-(benzylamino)-1H-indole-2-carboxylate 
• 101134-93-4 5-<<<5-(benzoylamino)-1H-indol-2-yl>carbonyl>amino>-1H-indole-2-carboxylic acid 
• 104713-40-8 2-({5-[(1H-indol-2-ylcarbonyl)amino]-1H-indol-2-yl}carbonyl)-1,2,8,8a-tetrahydro-7-methylcyclopropa[c]pyrrolo[3,2-e]indol-4(5H)-one 
• 101151-43-3 [2-(5-Benzyloxy-1-hydroxymethyl-8-methyl-1,6-dihydro-2H-pyrrolo[3,2-e]indole-3-carbonyl)-1H-indol-5-yl]-urea 
• 112089-95-9 Methanesulfonic acid 5-benzyloxy-8-methyl-3-(5-ureido-1H-indole-2-carbonyl)-1,2,3,6-tetrahydro-pyrrolo[3,2-e]indol-1-ylmethyl ester 
• 112243-84-2 5-(benzyloxy)-1,2,3,6-tetrahydro-8-methyl-3-<<5-<(1H-indol-2-ylcabonyl)amino>-1H-indol-2-yl>carbonyl>benzo<1,2-b:4,3-b'>dipyrrole-1-methanol 
• 112089-50-6 C₃₇H₂₈N₆O₄ 
• 112243-85-3 Methanesulfonic acid 5-benzyloxy-3-{4-[(1H-indole-2-carbonyl)-amino]-1H-indole-2-carbonyl}-8-methyl-1,2,3,6-tetrahydro-pyrrolo[3,2-e]indol-1-ylmethyl ester 
• 101134-53-6 5-Ureido-1H-indole-2-carboxylic acid [2-(5-benzyloxy-1-hydroxymethyl-8-methyl-1,6-dihydro-2H-pyrrolo[3,2-e]indole-3-carbonyl)-1H-indol-5-yl]-amide 
• 101134-52-5 5-Benzoylamino-1H-indole-2-carboxylic acid [2-(5-benzyloxy-1-hydroxymethyl-8-methyl-1,6-dihydro-2H-pyrrolo[3,2-e]indole-3-carbonyl)-1H-indol-5-yl]-amide 
• 112089-98-2 Methanesulfonic acid 5-benzyloxy-8-methyl-3-{5-[(5-ureido-1H-indole-2-carbonyl)-amino]-1H-indole-2-carbonyl}-1,2,3,6-tetrahydro-pyrrolo[3,2-e]indol-1-ylmethyl ester 

Relevant academic research and scientific papers

Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS

The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator, compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.

Expedient synthesis of 1-hydroxy-4- and 1-hydroxy-6-nitroindoles

Reaction of -chloroalkyl ketones with 1,3-dinitrobenzenes provides 2,4-dinitrobenzyl ketones which when reduced with tin(II) chloride form 6-nitro derivatives of 1-hydroxyindoles. An alternative approach is the condensation of 2,4- and 2,6-dinitrotoluenes

COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

Modulators of ATP-binding cassette transporters

Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.

Synthesis of some new biologically active 1,3,4-oxadiazolyl nitroindoles and a modified Fischer indole synthesis of ethyl nitro indole-2-carboxylates

An efficient and modified synthesis of ethyl-4-nitro/5-nitro/6-nitro and 7-nitroindole-2-carboxylates is described. Carbohydrazides of corresponding ethyl nitroindole-2-carboxylates underwent smooth one-step transformation to 1,3,4-oxadiazolyl nitroindole

Monocyte chemoattractant protein-1 inhibitor compounds

The invention concerns the use of a compound of the formula (I) in which Z, X, T, A, R1, R2, p and q have any of the meanings defined herein, and their pharmaceutically acceptable salts or in vivo hydrolysable esters, in the treatment of a disease or condition mediated by monocyte chemoattractant protein-1 (MCP-1). Certain of the components of formula (I) are novel and are provided, together with pharmaceutical compositions thereof, as further features of the invention.